Search

Your search keyword '"Sun, Clare"' showing total 483 results
Start Over Author "Sun, Clare"
483 results on '"Sun, Clare"'

1. Molecular map of chronic lymphocytic leukemia and its impact on outcome

Author

Knisbacher, Binyamin A, Lin, Ziao, Hahn, Cynthia K, Nadeu, Ferran, Duran-Ferrer, Martí, Stevenson, Kristen E, Tausch, Eugen, Delgado, Julio, Barbera-Mourelle, Alex, Taylor-Weiner, Amaro, Bousquets-Muñoz, Pablo, Diaz-Navarro, Ander, Dunford, Andrew, Anand, Shankara, Kretzmer, Helene, Gutierrez-Abril, Jesus, López-Tamargo, Sara, Fernandes, Stacey M, Sun, Clare, Sivina, Mariela, Rassenti, Laura Z, Schneider, Christof, Li, Shuqiang, Parida, Laxmi, Meissner, Alexander, Aguet, François, Burger, Jan A, Wiestner, Adrian, Kipps, Thomas J, Brown, Jennifer R, Hallek, Michael, Stewart, Chip, Neuberg, Donna S, Martín-Subero, José I, Puente, Xose S, Stilgenbauer, Stephan, Wu, Catherine J, Campo, Elias, and Getz, Gad

Subjects
Hematology, Clinical Research, Cancer, Human Genome, Rare Diseases, Biotechnology, Genetics, Lymphoma, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Immunoglobulin Variable Region, Mutation, Prognosis, Genomics, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Recent advances in cancer characterization have consistently revealed marked heterogeneity, impeding the completion of integrated molecular and clinical maps for each malignancy. Here, we focus on chronic lymphocytic leukemia (CLL), a B cell neoplasm with variable natural history that is conventionally categorized into two subtypes distinguished by extent of somatic mutations in the heavy-chain variable region of immunoglobulin genes (IGHV). To build the 'CLL map,' we integrated genomic, transcriptomic and epigenomic data from 1,148 patients. We identified 202 candidate genetic drivers of CLL (109 new) and refined the characterization of IGHV subtypes, which revealed distinct genomic landscapes and leukemogenic trajectories. Discovery of new gene expression subtypes further subcategorized this neoplasm and proved to be independent prognostic factors. Clinical outcomes were associated with a combination of genetic, epigenetic and gene expression features, further advancing our prognostic paradigm. Overall, this work reveals fresh insights into CLL oncogenesis and prognostication.

Published
2022

2. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Author

Roessner, Philipp M., Seufert, Isabelle, Chapaprieta, Vicente, Jayabalan, Ruparoshni, Briesch, Hannah, Massoni-Badosa, Ramon, Boskovic, Pavle, Benckendorff, Julian, Roider, Tobias, Arseni, Lavinia, Coelho, Mariana, Chakraborty, Supriya, Vaca, Alicia M., Sivina, Mariela, Muckenhuber, Markus, Rodriguez-Rodriguez, Sonia, Bonato, Alice, Herbst, Sophie A., Zapatka, Marc, Sun, Clare, Kretzmer, Helene, Naake, Thomas, Bruch, Peter-Martin, Czernilofsky, Felix, ten Hacken, Elisa, Schneider, Martin, Helm, Dominic, Yosifov, Deyan Y., Kauer, Joseph, Danilov, Alexey V., Bewarder, Moritz, Heyne, Kristina, Schneider, Christof, Stilgenbauer, Stephan, Wiestner, Adrian, Mallm, Jan-Philipp, Burger, Jan A., Efremov, Dimitar G., Lichter, Peter, Dietrich, Sascha, Martin-Subero, José I., Rippe, Karsten, and Seiffert, Martina

Published
2024
Full Text
View/download PDF

3. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)CLL/SLL Unmet Need

Author

Mato, Anthony R, Davids, Matthew S, Sharman, Jeff, Roeker, Lindsey E, Kay, Neil, Kater, Arnon P, Rogers, Kerry, Thompson, Meghan C, Rhodes, Joanna, Goy, Andre, Skarbnik, Alan, Schuster, Stephen J, Tam, Constantine S, Eyre, Toby A, O'Brien, Susan, Nabhan, Chadi, Lamanna, Nicole, Sun, Clare, Shadman, Mazyar, Pagel, John M, Ujjani, Chaitra, Brander, Danielle, Coombs, Catherine C, Jain, Nitin, Cheah, Chan Y, Brown, Jennifer R, Seymour, John F, and Woyach, Jennifer A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Hematology, Lymphoma, Cancer, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

Published
2022

4. Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia

Author

Biran, Anat, Yin, Shanye, Kretzmer, Helene, Ten Hacken, Elisa, Parvin, Salma, Lucas, Fabienne, Uduman, Mohamed, Gutierrez, Catherine, Dangle, Nathan, Billington, Leah, Regis, Fara Faye, Rassenti, Laura Z, Mohammad, Arman, Hoffmann, Gabriela Brunsting, Stevenson, Kristen, Zheng, Mei, Witten, Elizabeth, Fernandes, Stacey M, Tausch, Eugen, Sun, Clare, Stilgenbauer, Stephan, Brown, Jennifer R, Kipps, Thomas J, Aster, John C, Gnirke, Andreas, Neuberg, Donna S, Letai, Anthony, Wang, Lili, Carrasco, Ruben D, Meissner, Alexander, and Wu, Catherine J

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Lymphatic Research, Cancer, Cancer Genomics, Hematology, Human Genome, Lymphoma, Rare Diseases, 2.1 Biological and endogenous factors, Animals, Anti-Bacterial Agents, Apoptosis, Biomarkers, Tumor, Cell Proliferation, DNA Methyltransferase 3A, Daptomycin, Disease Models, Animal, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Mice, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Prognosis, Proto-Oncogene Proteins c-myc, RNA-Seq, Receptors, Notch, Survival Rate, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by disordered DNA methylation, suggesting these epigenetic changes might play a critical role in disease onset and progression. The methyltransferase DNMT3A is a key regulator of DNA methylation. Although DNMT3A somatic mutations in CLL are rare, we found that low DNMT3A expression is associated with more aggressive disease. A conditional knockout mouse model showed that homozygous depletion of Dnmt3a from B cells results in the development of CLL with 100% penetrance at a median age of onset of 5.3 months, and heterozygous Dnmt3a depletion yields a disease penetrance of 89% with a median onset at 18.5 months, confirming its role as a haploinsufficient tumor suppressor. B1a cells were confirmed as the cell of origin of disease in this model, and Dnmt3a depletion resulted in focal hypomethylation and activation of Notch and Myc signaling. Amplification of chromosome 15 containing the Myc gene was detected in all CLL mice tested, and infiltration of high-Myc-expressing CLL cells in the spleen was observed. Notably, hyperactivation of Notch and Myc signaling was exclusively observed in the Dnmt3a CLL mice, but not in three other CLL mouse models tested (Sf3b1-Atm, Ikzf3, and MDR), and Dnmt3a-depleted CLL were sensitive to pharmacologic inhibition of Notch signaling in vitro and in vivo. Consistent with these findings, human CLL samples with lower DNMT3A expression were more sensitive to Notch inhibition than those with higher DNMT3A expression. Altogether, these results suggest that Dnmt3a depletion induces CLL that is highly dependent on activation of Notch and Myc signaling. SIGNIFICANCE: Loss of DNMT3A expression is a driving event in CLL and is associated with aggressive disease, activation of Notch and Myc signaling, and enhanced sensitivity to Notch inhibition.

Published
2021

7. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Author

Zhang, Deyi, Harris, Hailey M., Chen, Jonathan, Judy, Jen, James, Gabriella, Kelly, Aileen, McIntosh, Joel, Tenn-McClellan, Austin, Ambing, Eileen, Tan, Ying Siow, Lu, Hao, Gajewski, Stefan, Clifton, Matthew C., Yung, Stephanie, Robbins, Daniel W., Pirooznia, Mehdi, Skånland, Sigrid S., Gaglione, Erika, Mhibik, Maissa, Underbayev, Chingiz, Ahn, Inhye E., Sun, Clare, Herman, Sarah E. M., Noviski, Mark, and Wiestner, Adrian

Published
2023
Full Text
View/download PDF

11. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

Author

Furman, Richard R., Byrd, John C., Owen, Roger G., O’Brien, Susan M., Brown, Jennifer R., Hillmen, Peter, Stephens, Deborah M., Chernyukhin, Nataliya, Lezhava, Tamara, Hamdy, Ahmed M., Izumi, Raquel, Patel, Priti, Baek, Marshall, Christian, Beth, Dyer, Martin J. S., Streetly, Matthew J., Sun, Clare, Rule, Simon, Wang, Michael, Ghia, Paolo, Jurczak, Wojciech, Pagel, John M., and Sharman, Jeff P.

Published
2021
Full Text
View/download PDF

12. MARCKS affects cell motility and response to BTK inhibitors in CLL

Author

Beckmann, Laura, Berg, Valeska, Dickhut, Clarissa, Sun, Clare, Merkel, Olaf, Bloehdorn, Johannes, Robrecht, Sandra, Seifert, Marc, da Palma Guerreiro, Alexandra, Claasen, Julia, Loroch, Stefan, Oliverio, Matteo, Underbayev, Chingiz, Vaughn, Lauren, Thomalla, Daniel, Hülsemann, Malte F., Tausch, Eugen, Fischer, Kirsten, Fink, Anna Maria, Eichhorst, Barbara, Sickmann, Albert, Wendtner, Clemens M., Stilgenbauer, Stephan, Hallek, Michael, Wiestner, Adrian, Zahedi, René P., and Frenzel, Lukas P.

Published
2021
Full Text
View/download PDF

14. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Author

Sun, Clare, Nierman, Pia, Kendall, Ellen K., Cheung, Jean, Gulrajani, Michael, Herman, Sarah E.M., Pleyer, Christopher, Ahn, Inhye E., Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Gaglione, Erika M., Harris, Hailey M., Pittaluga, Stefania, Wang, Min Hui, Patel, Priti, Farooqui, Mohammed Z.H., Izumi, Raquel, Hamdy, Ahmed, Covey, Todd, and Wiestner, Adrian

Published
2020
Full Text
View/download PDF

15. Fig S3 from Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Author

Alsadhan, Anfal, primary, Cheung, Jean, primary, Gulrajani, Michael, primary, Gaglione, Erika M., primary, Nierman, Pia, primary, Hamdy, Ahmed, primary, Izumi, Raquel, primary, Bibikova, Elena, primary, Patel, Priti, primary, Sun, Clare, primary, Covey, Todd, primary, Herman, Sarah E.M., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

19. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Author

Ahn, Inhye E., Farooqui, Mohammed Z.H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E.M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, and Wiestner, Adrian

Published
2018
Full Text
View/download PDF

20. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL‐leukemia

Author

Zhang, Jun, Seet, Christopher S, Sun, Clare, Li, Jing, You, Dewen, Volk, Andrew, Breslin, Peter, Li, Xingyu, Wei, Wei, Qian, Zhijian, Zeleznik-Le, Nancy J, Zhang, Zhou, and Zhang, Jiwang

Subjects
Stem Cell Research - Nonembryonic - Human, Pediatric Cancer, Hematology, Stem Cell Research, Genetics, Rare Diseases, Childhood Leukemia, Cancer, Pediatric, Stem Cell Research - Nonembryonic - Non-Human, Aetiology, 2.1 Biological and endogenous factors, Animals, Biomarkers, Tumor, CD11b Antigen, Cell Cycle Checkpoints, Cyclin-Dependent Kinase Inhibitor p27, Drug Resistance, Neoplasm, Gene Expression Regulation, Leukemic, Homeodomain Proteins, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Mice, Mice, Knockout, Myeloid Ecotropic Viral Integration Site 1 Protein, Neoplasm Proteins, Neoplastic Stem Cells, Proto-Oncogene Proteins c-kit, Proto-Oncogene Proteins c-myc, MLL-leukemia, p27(kip1), Leukemia stem cell, Quiescence, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

MLL (mixed-lineage leukemia)-fusion genes induce the development of leukemia through deregulation of normal MLL target genes, such as HOXA9 and MEIS1. Both HOXA9 and MEIS1 are required for MLL-fusion gene-induced leukemogenesis. Co-expression of HOXA9 and MEIS1 induces acute myeloid leukemia (AML) similar to that seen in mice in which MLL-fusion genes are over-expressed. p27(kip1) (p27 hereafter), a negative regulator of the cell cycle, has also been defined as an MLL target, the expression of which is up-regulated in MLL leukemic cells (LCs). To investigate whether p27 plays a role in the pathogenesis of MLL-leukemia, we examined the effects of p27 deletion (p27(-/-)) on MLL-AF9 (MA9)-induced murine AML development. HOXA9/MEIS1 (H/M)-induced, p27 wild-type (p27(+/+)) and p27(-/-) AML were studied in parallel as controls. We found that LCs from both MA9-AML and H/M-AML can be separated into three fractions, a CD117(-)CD11b(hi) differentiated fraction as well as CD117(+)CD11b(hi) and CD117(+)CD11b(lo), two less differentiated fractions. The CD117(+)CD11b(lo) fraction, comprising only 1-3% of total LCs, expresses higher levels of early hematopoietic progenitor markers but lower levels of mature myeloid cell markers compared to other populations of LCs. p27 is expressed and is required for maintaining the quiescent and drug-resistant states of the CD117(+)CD11b(lo) fraction of MA9-LCs but not of H/M-LCs. p27 deletion significantly compromises the leukemogenic capacity of CD117(+)CD11b(lo) MA9-LCs by reducing the frequency of leukemic stem cells (LSCs) but does not do so in H/M-LCs. In addition, we found that p27 is highly expressed and required for cell cycle arrest in the CD117(-)CD11b(hi) fraction in both types of LCs. Furthermore, we found that c-Myc expression is required for maintaining LCs in an undifferentiated state independently of proliferation. We concluded that p27 represses the proliferation of LCs, which is specifically required for maintaining the quiescent and drug-resistant states of a small subset of MA9-LSCs in collaboration with the differentiation blockage function of c-Myc.

Published
2013

21. Supplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Methods S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

24. Data from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

25. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.

Author

Alsadhan, Anfal, primary, Chen, Jonathan, additional, Gaglione, Erika M., additional, Underbayev, Chingiz, additional, Tuma, Pamela L., additional, Tian, Xin, additional, Freeman, Lita A., additional, Baskar, Sivasubramanian, additional, Nierman, Pia, additional, Soto, Susan, additional, Itsara, Andy, additional, Ahn, Inhye E., additional, Sun, Clare, additional, Bibikova, Elena, additional, Hartmann, Tanja Nicole., additional, Mhibik, Maissa, additional, and Wiestner, Adrian, additional

Published
2023
Full Text
View/download PDF

28. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.

Author

Tomasulo, Emily, Paul, Shira, Rui Mu, Xin Tian, Chen, Jonathan, Pleyer, Christopher, Wiestner, Adrian, and Sun, Clare

Subjects
BRUTON tyrosine kinase, BOOSTER vaccines, HEPATITIS B vaccines, CHRONIC lymphocytic leukemia, FLUDARABINE, PROTEIN-tyrosine kinase inhibitors, SARS-CoV-2
Abstract

B-cell targeted therapies, including anti-CD20 monoclonal antibodies (mAb) and Bruton’s tyrosine kinase inhibitors (BTKi), further suppress antibody (Ab) response to vaccines in patients with chronic lymphocytic leukemia (CLL). We conducted a prospective cohort study of SARS-CoV-2 vaccination in 81 CLL patients receiving BTKi (n=54), venetoclax (VEN, n=9), or who were treatment naïve (TN, n=18). Anti-spike Ab were detected in 53% of patients on BTKi post-primary series and 84% post-booster, 57% of patients on VEN post-primary series and 50% post-booster, and 67% of TN patients post-primary series and 87% post-booster. T-cell response to the primary series was independent of Ab response. At the time of booster, 12 patients interrupted BTKi (median 21d, range 8–22) and 33 continued BTKi. Among patients with detectable Ab post-booster, those who interrupted BTKi (n=10) had significantly higher Ab titers (median 7149 units/mL) compared with patients who continued BTKi (n=27, median 2071 units/mL, p = .04). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Supplementary Table 2 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 5 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

32. Oligos and Primers - related to Methods from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

33. Data from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 1 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 6 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 7 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures and Legends from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 4 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 3 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

45. Conflict of Interest Form from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Author

Niemann, Carsten U., primary, Herman, Sarah E.M., primary, Maric, Irina, primary, Gomez-Rodriguez, Julio, primary, Biancotto, Angelique, primary, Chang, Betty Y., primary, Martyr, Sabrina, primary, Stetler-Stevenson, Maryalice, primary, Yuan, Constance M., primary, Calvo, Katherine R., primary, Braylan, Raul C., primary, Valdez, Janet, primary, Lee, Yuh Shan, primary, Wong, Deanna H., primary, Jones, Jade, primary, Sun, Clare, primary, Marti, Gerald E., primary, Farooqui, Mohammed Z.H., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

46. Supplementary tables and figure legends from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Author

Niemann, Carsten U., primary, Herman, Sarah E.M., primary, Maric, Irina, primary, Gomez-Rodriguez, Julio, primary, Biancotto, Angelique, primary, Chang, Betty Y., primary, Martyr, Sabrina, primary, Stetler-Stevenson, Maryalice, primary, Yuan, Constance M., primary, Calvo, Katherine R., primary, Braylan, Raul C., primary, Valdez, Janet, primary, Lee, Yuh Shan, primary, Wong, Deanna H., primary, Jones, Jade, primary, Sun, Clare, primary, Marti, Gerald E., primary, Farooqui, Mohammed Z.H., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results